Oliver J.

Prof. Dr. Oliver J.

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJonas Weinmann
Jonas Weinmann
SWSabrina Weis
Sabrina Weis
JSJosefine Sippel
Josefine Sippel
WTWarut Tulalamba
Warut Tulalamba
ARAnca Remes
Anca Remes
DGDirk Grimm
Dirk Grimm
Adeno-associated virus (AAV) forms the basis for several commercial gene therapy products and for countless gene transfer vectors derived from natural or synthetic viral isolates that are under intense preclinical evaluation. Here, we report a versatile pipeline that enables the direct side-by-side comparison of pre-selected AAV capsids in high-throughput and in the same animal, by combining DNA/RNA barcoding with multiplexed next-generation sequencing. For validation, we create three independent libraries comprising 183 different AAV variants including widely used benchmarks and screened them in all major tissues in adult mice. Thereby, we discover a peptide-displaying AAV9 mutant called AAVMYO that exhibits superior efficiency and specificity in the musculature including skeletal muscle, heart and diaphragm following peripheral delivery, and that holds great potential for muscle gene therapy. Our comprehensive methodology is compatible with any capsids, targets and species, and will thus facilitate and accelerate the stratification of optimal AAV vectors for human gene therapy.

25 August 2023 in Science
Verified
Journal Article
Closed access
JWJulian Wagner
Julian Wagner
LTLukas S. Tombor
Lukas S. Tombor
PMPedro Felipe Malacarne
Pedro Felipe Malacarne
LKLisa-Maria Kettenhausen
Lisa-Maria Kettenhausen
JPJosefine Panthel
Josefine Panthel
DBDittmar Böckler
Dittmar Böckler
Aging is a major risk factor for impaired cardiovascular health. Because the aging myocardium is characterized by microcirculatory dysfunction, and because nerves align with vessels, we assessed the impact of aging on the cardiac neurovascular interface. We report that aging reduces nerve density in the ventricle and dysregulates vascular-derived neuroregulatory genes. Aging down-regulates microRNA 145 (miR-145) and derepresses the neurorepulsive factor semaphorin-3A. miR-145 deletion, which increased Sema3a expression or endothelial Sema3a overexpression, reduced axon density, mimicking the aged-heart phenotype. Removal of senescent cells, which accumulated with chronological age in parallel to the decline in nerve density, rescued age-induced denervation, reversed Sema3a expression, preserved heart rate patterns, and reduced electrical instability. These data suggest that senescence-mediated regulation of nerve density contributes to age-associated cardiac dysfunction.

11 December 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LLLorenz H. Lehmann
Lorenz H. Lehmann
ZJZegeye H Jebessa
Zegeye H Jebessa
MKMichael M Kreusser
Michael M Kreusser
AHAxel Horsch
Axel Horsch
THTao He
Tao He
JBJohannes Backs
Johannes Backs

9 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYann W. Yap
Yann W. Yap
PRPatricia Rusu
Patricia Rusu
ACAndrea Y. Chan
Andrea Y. Chan
BFBarbara C. Fam
Barbara C. Fam
AJAndreas Jungmann
Andreas Jungmann
Adam J. RoseAdam J. Rose
Adam J. Rose
Dietary protein dilution (DPD) promotes metabolic-remodelling and -health but the precise nutritional components driving this response remain elusive. Here, by mimicking amino acid (AA) supply from a casein-based diet, we demonstrate that restriction of dietary essential AA (EAA), but not non-EAA, drives the systemic metabolic response to total AA deprivation; independent from dietary carbohydrate supply. Furthermore, systemic deprivation of threonine and tryptophan, independent of total AA supply, are both adequate and necessary to confer the systemic metabolic response to both diet, and genetic AA-transport loss, driven AA restriction. Dietary threonine restriction (DTR) retards the development of obesity-associated metabolic dysfunction. Liver-derived fibroblast growth factor 21 is required for the metabolic remodelling with DTR. Strikingly, hepatocyte-selective establishment of threonine biosynthetic capacity reverses the systemic metabolic response to DTR. Taken together, our studies of mice demonstrate that the restriction of EAA are sufficient and necessary to confer the systemic metabolic effects of DPD.

18 March 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
JOJürgen G. Okun
Jürgen G. Okun
PRPatricia Rusu
Patricia Rusu
ACAndrea Y. Chan
Andrea Y. Chan
YWYuqin Wu
Yuqin Wu
YYYann W. Yap
Yann W. Yap
Adam J. RoseAdam J. Rose
Adam J. Rose

23 September 2022 in Science Advances
Verified
Journal Article
Open access
JAJihad El Andari
Jihad El Andari
EREdith Renaud-Gabardos
Edith Renaud-Gabardos
WTWarut Tulalamba
Warut Tulalamba
JWJonas Weinmann
Jonas Weinmann
LMLouise Mangin
Louise Mangin
DGDirk Grimm
Dirk Grimm
Bioengineering of viral vectors for therapeutic gene delivery is a pivotal strategy to reduce doses, facilitate manufacturing, and improve efficacy and patient safety. Here, we engineered myotropic adeno-associated viral (AAV) vectors via a semirational, combinatorial approach that merges AAV capsid and peptide library screens. We first identified shuffled AAVs with increased specificity in the murine skeletal muscle, diaphragm, and heart, concurrent with liver detargeting. Next, we boosted muscle specificity by displaying a myotropic peptide on the capsid surface. In a mouse model of X-linked myotubular myopathy, the best vectors—AAVMYO2 and AAVMYO3—prolonged survival, corrected growth, restored strength, and ameliorated muscle fiber size and centronucleation. In a mouse model of Duchenne muscular dystrophy, our lead capsid induced robust microdystrophin expression and improved muscle function. Our pipeline is compatible with complementary AAV genome bioengineering strategies, as demonstrated here with two promoters, and could benefit many clinical applications beyond muscle gene therapy.